The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies
Open accessAbstract
hnRNP K regulates cellular programs, and changes in its expression and mutational status have been implicated in neoplastic malignancies. To directly examine its role in tumorigenesis, we generated a mouse model harboring an Hnrnpk knockout allele (Hnrnpk(+/-)). Hnrnpk haploinsufficiency resulted in reduced survival, increased tumor formation, genomic instability, and the development of transplantable hematopoietic neoplasms with myeloproliferation. Reduced hnRNP K expression attenuated p21 activation, downregulated C/EBP levels, and activated STAT3 signaling. Additionally, analysis of samples from primary acute myeloid leukemia patients harboring a partial deletion of chromosome 9 revealed a significant decrease in HNRNPK expression. Together, these data implicate hnRNP K in the development of hematological disorders and suggest hnRNP K acts as a tumor suppressor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the expression of hnRNP K (40), SRSF3 (SRp20) (41), and YB-1 (42) has been shown to be altered in AML, but also to contribute to leukemia progression.”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage
Moumen, A., Masterson, P., O'Connor, M. J., & Jackson, S. P. (2005) · Cell · doi:10.1016/j.cell.2005.09.032 · Cited by 350
RetractedA new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
Hematopoietic stem cell: self‐renewal versus differentiation
Seita, J., & Weissman, I. L. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.86 · Cited by 997
Therapeutic Advances in Acute Myeloid Leukemia
Burnett, A. K., Wetzler, M., & Löwenberg, B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1820 · Cited by 806
Mrózek, K., Marcucci, G., Paschka, P., Whitman, S. P., & Bloomfield, C. D. (2006) · Blood · doi:10.1182/blood-2006-06-001149 · Cited by 554
Ostareck, D. H., Ostareck‐Lederer, A., Wilm, M. S., Thiele, B. J., Mann, M., & Hentze, M. W. (1997) · Cell · doi:10.1016/s0092-8674(00)80241-x · Cited by 502
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V., Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 362
Cited by
Sorted by citations
The hnRNP family: insights into their role in health and disease
Geuens, T., Bouhy, D., & Timmerman, V. (2016) · Human Genetics · doi:10.1007/s00439-016-1683-5 · Cited by 1,096
RNA-Binding Proteins in Cancer: Old Players and New Actors
Pereira, B., Billaud, M., & Almeida, R. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.05.003 · Cited by 774
RNA splicing factors as oncoproteins and tumour suppressors
Dvinge, H., Kim, E. H., Abdel-Wahab, O. I., & Bradley, R. K. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.51 · Cited by 702
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Alternative splicing and cancer: a systematic review
Zhang, Y., Qian, J., Gu, C., & Yang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00486-7 · Cited by 540
Metadata
- Authors
- Gallardo, M., Lee, H. J., Zhang, X., Bueso-Ramos, C., Pageon, L. R., McArthur, M., Multani, A., Nazha, A., Manshouri, T., Parker-Thornburg, J., Rapado, I., Quintas-Cardama, A., Kornblau, S. M., Martinez-Lopez, J., & Post, S. M.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Corresponding author
- Post, Sean M.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 28
- Issue
- 4
- Pages
- 486-499
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4652598
- OpenAlex
- W2168139795
- Cited by
- 145
- References
- 36
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 4 · 2023: 15 · 2022: 15 · 2021: 21 · 2020: 13 · 2019: 22 · 2018: 14 · 2017: 12 · 2016: 5 · 2015: 1
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (P50CA100632, CA-16672, P50 CA1000632-09, P30CA016672)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- hnRNP K, haploinsufficiency, tumor suppressor, hematologic malignancies, acute myeloid leukemia, chromosome 9 deletion, myeloproliferation, STAT3 signaling, p21, C/EBP, genomic instability, cell proliferation, cell differentiation
- MeSH terms
- Animals, Cell Differentiation, Cells, Cultured, Chromosomes, Human, Pair 9, Humans, Ribonucleoproteins, Signal Transduction, Gene Expression Regulation, Neoplastic, Survival Analysis, Hematologic Neoplasms, Heterogeneous-Nuclear Ribonucleoprotein K, Chromosomal Instability, Cell Proliferation, Mice, Gene Knockout Techniques, Haploinsufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
